Agilent Technologies, Inc. (A) Stock Analysis

50.0/100
Hold ✓ Halal Healthcare
Price $173.96
Market Cap $49.05B
52-Week Change +18.43%

Is A a good investment?

Agilent Technologies, Inc. (A) has a Plutrex AI rating of 50.0/100 as of November 12, 2026, indicating a Hold consensus. The stock is halal-compliant per AAOIFI standards. Key strength: Industry-best profitability moat: gross margin 53.7% (+28.7% vs. peers), operating margin 24.5% (+52.0% vs. peers), ROE 21.0% (+92.9% vs. peers) — durable competitive advantages that peers cannot easily replicate, justifying quality premium over time. Main concern: Valuation remains deeply stretched: PEG 3.53x on 8.0% next-year EPS growth implies a 253% premium to fair-value benchmark of 1.0x; analyst consensus target $178.82 implies only +1.1% upside from $176.95 — zero margin of safety for new buyers, and downside to stop ($141) of -20.3% dwarfs the 1.1% potential upside.

Investment Summary

Agilent Technologies (A) is a best-in-class Medical Diagnostics & Research compounder with industry-leading profitability (gross margin 53.7% vs. industry 41.8%, net margin 19.5% vs. industry 11.7%, ROE 21.0% vs. industry 10.9%) but remains deeply overvalued at a PEG of 3.53x against 8.0% forward EPS growth. The stock has pulled back $4.59 (-2.5%) from $181.54 to $176.95 since the prior report, which is a modest improvement in risk/reward but nowhere near sufficient to justify new entry. The analyst consensus target of $178.82 implies only +1.1% upside from current price — not a compelling entry point. FCF of $1.267B supports ongoing AI initiatives (Proscia acquisition, Gen5 AI Cell Identification, NovoStation), and news flow is uniformly positive with new product launches and sector tailwinds, but none of these catalysts are yet translating into consensus EPS estimate upgrades that would narrow the 42.6% forward growth deficit vs. industry peers. HOLD for existing owners; WAIT for $148-$156 for new buyers.

Key Strengths

Key Concerns

Plutrex 10-Factor AI Breakdown

Financial Health
76/100
Growth Potential
30/100
Valuation
18/100
Profitability
93/100
Debt Management
86/100
Analyst Sentiment
65/100
Technical Momentum
48/100
Insider Confidence
55/100
News Sentiment
85/100

Fundamental Analysis

Profitability (90/100 standalone, 96/100 industry-adjusted): Gross margin 53.7% is +28.7% above the industry average of 41.8% — the widest margin in the peer group, reflecting genuine pricing power and proprietary product positioning. Operating margin 24.5% is +52.0% above peers (industry avg 16.1%). Net margin 19.5% is +66.8% above peers (industry avg 11.7%). ROE 21.0% is +92.9% above industry average of 10.9% — nearly double peer efficiency in capital deployment. FCF of $1.267B (prior period $1.436B, modest decline) confirms high earnings quality. Debt-to-equity 0.50x vs. industry 0.619x — conservatively financed. Cash $1.758B provides acquisition and R&D firepower without external financing needs. Growth (30/100): Next-year EPS growth 8.0% vs. industry 14.0% — Agilent grows at 57 cents on the dollar relative to peers. Five-year EPS growth 9.9% vs. industry 12.6% — the structural growth gap persists even on a medium-term horizon. Revenue growth 8.1% vs. industry 15.8% — the industry is growing topline at nearly twice Agilent's pace. Historical earnings growth 8.5% vs. industry 30.4% — the most dramatic gap, confirming Agilent's mature compounder status. Valuation (15/100): P/E 34.84x vs. industry 39.53x (11.9% discount to peers). PEG 3.53x vs. industry 5.20x (32.1% discount to peers). While relatively cheaper than peers, absolute PEG of 3.53x remains extreme — paying 253% above the 1.0x fair-value benchmark for 8-10% growth. Fair-value P/E for 9.9% five-year growth would be approximately 15-20x, implying intrinsic value of roughly $76-$102; with a generous quality premium of 50%, fair value reaches ~$114-$153. Analyst consensus $178.82 vs. current $176.95 = +1.1% implied upside — essentially zero margin of safety.

News Sentiment

Agilent Technologies is on the move — and not just in the lab. The life sciences giant has been making a string of strategic moves that signal it's serious about becoming a force in the rapidly growing world of medical diagnostics and research technology. The biggest story: Agilent has completed its acquisition of Proscia, a digital pathology AI company, with a $30 million contingent payment tied to hitting specific growth targets — a structure that keeps Proscia's management team hungry and aligned with investors. Meanwhile, Agilent expanded its tumor profiling portfolio with a new SureSelect Cancer Research Pan panel developed in collaboration with the prestigious Roswell Park Comprehensive Cancer Center, adding serious scientific credibility to its oncology offerings. On the instruments side, the new 5987A Mass Selective Detector with GC Assist promises faster, smarter laboratory workflows — the kind of upgrade that keeps existing customers locked in and new ones interested. Perhaps most importantly for investors, CNBC's Jim Cramer recently called out life science supply and research instrument companies — specifically the category Agilent plays in — as 'the new techs taking over,' even as he labeled Big Tech as 'millstones.' That kind of Wall Street spotlight, combined with Agilent's upcoming Q4 earnings report, has investors watching closely to see whether the company's AI and automation investments are finally showing up in the numbers.

Risk Assessment

PRIMARY RISK: Multiple compression. At P/E 34.84x and PEG 3.53x on 8.0% forward EPS growth, any earnings miss or growth deceleration could compress the multiple toward 25-28x (still generous), implying a stock price of $125-$142 — a 20-30% drawdown from current levels. The stock has already pulled back from $181.54 to $176.95, suggesting the market is beginning to reflect this risk. SECONDARY RISK: AI product cycle fails to close growth gap. If Proscia, Gen5, and NovoStation do not generate meaningful EPS estimate revisions over the next 2-4 quarters, the structural growth deficit vs. industry (8.0% vs. 14.0% forward EPS) will continue to pressure the multiple, particularly if faster-growing peers attract incremental capital. MITIGANTS: (1) Profitability moat provides earnings floor — 53.7% gross margins and $1.267B FCF mean the company can sustain operations and buybacks even in a growth slowdown. (2) Conservative balance sheet (D/E 0.50x, $1.758B cash) prevents balance sheet distress. (3) Relative valuation discount to peers (-11.9% P/E, -32.1% PEG) limits extreme downside versus sector. ENTRY AT $148-$156: At $152 midpoint, P/E falls to approximately 29.9x, PEG to approximately 2.99x, and upside to analyst consensus of $178.82 is +17.6% vs. downside to stop of $141 is -7.2% — risk/reward of approximately 2.4:1, minimally acceptable for a medium-conviction quality compounder.

Related Halal Stocks

Related Stocks

Frequently Asked Questions

Is A a halal stock?

Yes, Agilent Technologies, Inc. (A) is halal-compliant per AAOIFI standards as of the latest quarterly review.

What is Plutrex's AI rating for A?

Agilent Technologies, Inc. (A) has a Plutrex AI rating of 50.0/100 with a Hold consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.

Is A a good investment?

According to Plutrex AI, A has a Hold rating (50.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.

How can I invest in A?

US stocks like A can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. ElBarake provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.

What are the main risks of investing in A?

Plutrex AI identifies the main risks for A by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.

Chat with ElBarake AI about A

Ask anything about this stock and get an instant AI-powered answer — free, no signup required.

Open A in ElBarake